Difference between revisions of "Alvocidib (Flavopiridol)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence !Comparator !Efficacy |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy |-") |
Warner-admin (talk | contribs) m (Text replacement - "Cytarabine (Cytosar)" to "Cytarabine (Ara-C)") |
||
| Line 26: | Line 26: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Alvocidib (Flavopiridol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 to 3 | *[[Alvocidib (Flavopiridol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
| − | *[[Cytarabine ( | + | *[[Cytarabine (Ara-C)]] 667 mg/m<sup>2</sup>/day IV continuous infusion on days 6 to 8 (total dose: 2000 mg/m<sup>2</sup>) |
*[[Mitoxantrone (Novantrone)]] 40 mg/m<sup>2</sup> IV once on day 9 | *[[Mitoxantrone (Novantrone)]] 40 mg/m<sup>2</sup> IV once on day 9 | ||
Revision as of 15:45, 28 January 2019
Mechanism of action
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO
Preliminary data
Acute myeloid leukemia
FLAM
| back to top |
FLAM: FLavopiridol (Alvocidib), Ara-C (Cytarabine), Mitoxantrone
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Zeidner et al. 2015 (JHOC-J1101) | Randomized Phase II (E) | 7+3d, high-dose dauno | Superior CR rate |
Chemotherapy
- Alvocidib (Flavopiridol) 50 mg/m2 IV once per day on days 1 to 3
- Cytarabine (Ara-C) 667 mg/m2/day IV continuous infusion on days 6 to 8 (total dose: 2000 mg/m2)
- Mitoxantrone (Novantrone) 40 mg/m2 IV once on day 9
One course
References
- JHOC-J1101: Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article contains verified protocol link to PMC article PubMed
Chronic lymphocytic leukemia (CLL/SLL)
History of changes in FDA indication
- 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
- 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)
Also known as
- Code names: HMR 1275, L-868275